Several studies of different cancer types showed that high tumour mutational burden, MSI, and PD-1/PD-L1 immunohistochemical status in tumour tissues could identify patients who would respond to immune checkpoint inhibitors (ICIs). This evidence concerns the gene CD274 and cancer.